## Bioprinting and Organ Regeneration Imagine a machine that could print a replacement kidney, layer by living layer, customized to your body, ready for transplant. It sounds like science fiction, and in the movie *Elysium*, it essentially is. But the real-world technology of bioprinting is advancing faster than many people realize, and it is raising important questions about who gets access to the medical breakthroughs of the future. ### What Is Bioprinting? Bioprinting is a form of 3D printing that uses living cells as its "ink." Instead of depositing layers of plastic or metal, a bioprinter deposits layers of biological material, building up structures that can mimic the architecture of living tissues and, eventually, organs. The basic concept draws on the same additive manufacturing principles used in industrial 3D printing: a digital blueprint guides the precise deposition of material, layer by layer, until a three-dimensional object is formed. But working with living cells introduces a level of complexity that goes far beyond engineering. Cells need to be kept alive during the printing process, supplied with nutrients, and organized in ways that allow them to function as they would in a living body. Researchers have already bioprinted relatively simple structures, including skin patches, cartilage, and blood vessels. More complex tissues, such as liver tissue that can metabolize drugs, have been produced for laboratory testing. But printing a fully functional organ, with its intricate network of blood vessels, nerves, and multiple cell types, remains a formidable challenge. ### How the Book Explores It *Films from the Future* (Chapter 6) uses the movie *Elysium* to explore bioprinting and the broader question of medical technology access. In the film, set in 2154, the wealthy elite live on a pristine space station called Elysium, where advanced medical technology, including devices that can rebuild a human body from scratch, is freely available. Meanwhile, the vast majority of humanity is stuck on an overcrowded, polluted Earth with no access to these life-saving technologies. The film's medical "med-bays" are science fantasy, but the book uses them to highlight a very real concern: as medical technologies like bioprinting advance, who will be able to afford them? The history of medical innovation suggests that breakthroughs tend to be available first to the wealthy, and the gap between what is technically possible and what is broadly accessible can persist for decades. ### Where Things Stand Today Bioprinting technology has made significant strides. Companies and research labs around the world are working on bioprinted tissues for drug testing, surgical planning, and eventually transplantation. Bioprinted skin grafts are in clinical development. Researchers have printed miniature "organoids," simplified versions of organs that can be used to study disease and test treatments. And the dream of printing full-sized, transplantable organs, while still distant, is driving substantial investment and research. The organ transplant shortage provides a powerful motivation. Thousands of people die each year waiting for donor organs. If bioprinting can deliver on its promise, it could eliminate transplant waiting lists entirely, providing patients with custom-built organs made from their own cells, eliminating the risk of rejection. ### Why It Matters Bioprinting sits at the intersection of two major themes in *Films from the Future*: the extraordinary potential of converging technologies, and the danger that their benefits will be distributed unequally. The technology itself is a testament to what becomes possible when biology, materials science, engineering, and computing come together. But the social questions it raises are just as important as the technical ones. If bioprinted organs become available but cost hundreds of thousands of dollars, the technology could deepen health inequalities rather than reduce them. If access is determined by wealth or geography, we could end up with a world that looks uncomfortably like the one depicted in *Elysium*, where the best medical care is reserved for those who can pay for it. The book argues that thinking about access and equity needs to happen alongside the technical development, not as an afterthought. The time to decide what kind of future we want from bioprinting is now, while the technology is still being shaped. ### Explore Further - [Cloning and Reproductive Biology](https://spoileralert.wtf/md-files/est_cloning.md) — another approach to growing biological material - [Human Augmentation and Body Modification](https://spoileralert.wtf/md-files/est_human_augmentation.md) — the broader landscape of rebuilding the human body - [Automation and Robotics](https://spoileralert.wtf/md-files/est_automation.md) — also explored through *Elysium* - [Power, Privilege, and Access](https://spoileralert.wtf/md-files/rei_power_privilege_access.md) — who benefits from advanced medical technology? ## Further Reading - [Social Inequity and Elysium — Moviegoer's Guide to the Future (Future of Being Human)](https://www.futureofbeinghuman.com/p/social-inequity-elysium) — Andrew Maynard explores the *Elysium* chapter from *Films from the Future*, examining what happens when advanced medical technologies including bioprinting-like capabilities are available only to the wealthy, connecting regenerative medicine to urgent questions about equity and access. - [The Moviegoer's Guide to the Future — ASU Course (Andrew Maynard)](https://futureofbeinghuman.asu.edu/fis-338-the-moviegoers-guide-to-the-future/) — Maynard's undergraduate course based on *Films from the Future*, which uses films including *Elysium* to explore the complex relationships between emerging technologies, social justice, equity, and what it means to be human — providing the educational context for the book's approach to bioprinting and access. - [A Roadmap for the Implementation of 3D-Printed Organs in Healthcare — Zhang, Zhang & Yin, *Device* (Cell Press, 2025)](https://www.cell.com/device/fulltext/S2666-9986(25)00160-7) — A comprehensive roadmap mapping the path from current bioprinting capabilities to fully functional organ replacement, covering clinical applications across multiple organ systems, how patient-derived cells could eliminate transplant rejection, and a clear-eyed assessment of remaining technical hurdles. - [Assessing the Landscape of Clinical and Observational Trials Involving Bioprinting — Briones et al., *3D Printing in Medicine* (2025)](https://link.springer.com/article/10.1186/s41205-025-00253-2) — This scoping review found only 11 qualifying clinical bioprinting trials registered globally between 2016 and 2023, revealing how early the field remains in clinical translation — documenting trials implanting bioprinted blood vessels, trachea, external ears, and wound dressings alongside observational studies using bioprinted tissue for cancer precision medicine. - [Bioprinted Constructs in the Regulatory Landscape — Perin, Lim et al., *Advanced Materials* (January 2026)](https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202504037) — A landmark review examining the fragmented regulatory landscape for bioprinted products across the EU, US, China, and Australia, tracing how bioprinted products fall between existing categories for medical devices, biologics, and tissue-engineered products — arguing that regulatory harmonization is essential to prevent access inequities as the technology matures. - [A Breakthrough in Bioprinting May Soon Lead to 3D-Printed Blood Vessels — Northeastern University (February 2025)](https://news.northeastern.edu/2025/02/20/3d-printed-blood-vessels/) — Reports on a newly patented elastic hydrogel material that solves a key barrier in bioprinting: creating soft tissues that can stretch and recoil like natural blood vessels. The biodegradable material allows cells to gradually replace the scaffold with their own collagen and elastin. - [New 3D Bioprinting Technique May Improve Production of Engineered Tissue — MIT News (September 2025)](https://news.mit.edu/2025/new-3d-bioprinting-technique-may-improve-production-engineered-tissue-0917) — MIT and Polytechnic University of Milan researchers developed a low-cost (under $500), AI-driven monitoring platform that can be added to any standard bioprinter, enabling real-time detection of print defects and automated parameter correction — addressing the quality-control gap between laboratory bioprinting and reproducible clinical-grade tissue fabrication.